Progress and clinical application of immunological detection technology for Mycobacterium tuberculosis infection

doi:10.19982/j.issn.1000-6621.20220103

Abstract

Abstract:

In the world and China, tuberculosis is still one of the infectious diseases requiring more attention to the prevention and control. Although the positive detection of Mycobacterium tuberculosis nucleic acid has been defined as one of the basis for the diagnosis of tuberculosis, there are still a large number of tuberculosis patients with negative etiology in clinic and need to rely on immunological detection technology for auxiliary diagnosis. The immunopathological response and anti-tuberculosis immune response caused by Mycobacterium tuberculosis infection are the basis for the development of immunological technologies. Various kinds of cells, cytokines, chemokines, and antibodies, etc., involved in different stages of the immune response, are all potential targets for immunological diagnosis. In recent years, a number of new immunological technologies have been developed based on these targets, including interferon-γ release assay, new tuberculin test, IP-10 test and IFN-γ/IL-2 dual release assay, offers new hopes for diagnosis of Mycobacterium tuberculosis infection and tuberculosis. In addition, some new protein biomarkers and poly-functional lymphocytes in the development process also show good potential diagnostic values. Herein, the current application status, advantages and disadvantages of immune diagnostic technologies that have been used in clinical practice are reviewed, and biomarkers and other potential targets that may be used in clinic in the future are discussed.

Key words: Mycobacterium tuberculosis, Infection, Immunity, Clinical laboratory techniques

CLC Number:

R378.91+1

JIA Hong-yan, DONG Jing, ZHANG Zong-de, PAN Li-ping. Progress and clinical application of immunological detection technology for Mycobacterium tuberculosis infection[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 720-726. doi: 10.19982/j.issn.1000-6621.20220103

Figures/Tables 1

References 65

[1]	Cohen A, Mathiasen VD, Schön T, et al. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J, 2019, 54(3):1900655. doi: 10.1183/13993003.00655-2019. doi: 10.1183/13993003.00655-2019 URL
[2]	Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis, 2015, 15(3):310-319. doi: 10.1016/S1473-3099(14)71085-0. doi: 10.1016/S1473-3099(14)71085-0 URL
[3]	高磊, 张慧, 胡茂桂, 等. 基于多中心调查数据和空间统计模型的全国结核分枝杆菌潜伏感染率估算. 中国防痨杂志, 2022, 44(1):54-59. doi: 10.19982/j.issn.1000-6621.20210661. doi: 10.19982/j.issn.1000-6621.20210661
[4]	中国疾病预防控制中心. 2018年全国结核病防治工作会议资料汇编. 北京:中国疾病预防控制中心, 2018.
[5]	World Health Organization. Commercial serodiagnostic testsfor diagnosis of tuberculosis policy statement. Geneva: World Heath Organization, 2011.
[6]	张薇, 赵立. 结核分枝杆菌感染的实验室诊断方法及检测技术研究进展. 国际呼吸杂志, 2019, 39(20):1586-1591. doi: 10.3760/cma.j.issn.1673-436X.2019.20.014. doi: 10.3760/cma.j.issn.1673-436X.2019.20.014
[7]	Lawn SD. Advances in Diagnostic Assays for Tuberculosis. Cold Spring Harb Perspect Med, 2015, 5(12):a017806. doi: 10.1101/cshperspect.a017806. doi: 10.1101/cshperspect.a017806
[8]	《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础学组和临床学组. 现阶段结核抗体检测在我国临床应用的专家共识. 中国防痨杂志, 2018, 40(1):9-13. doi: 10.3969/j.issn.1000-6621.2018.01.004. doi: 10.3969/j.issn.1000-6621.2018.01.004
[9]	杨蕾, 曹俊, 卢锦标, 等. 血清学抗体检测菌阴肺结核存在的问题讨论. 中华微生物学和免疫学杂志, 2017, 37(10):785-789. doi: 10.3760/cma.j.issn.0254-5101.2017.10.011. doi: 10.3760/cma.j.issn.0254-5101.2017.10.011
[10]	Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med, 2008, 149(3):177-184. doi: 10.7326/0003-4819-149-3-200808050-00241. doi: 10.7326/0003-4819-149-3-200808050-00241 URL
[11]	Ruhwald M, Aggerbeck H, Gallardo RV, et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med, 2017, 5(4):259-268. doi: 10.1016/S2213-2600(16)30436-2. doi: 10.1016/S2213-2600(16)30436-2 pmid: 28159608
[12]	中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8):761-768. doi: 10.3969/i.issn.1000-6621.2020.08.001. doi: 10.3969/i.issn.1000-6621.2020.08.001
[13]	中华医学会结核病学分会. 结核分枝杆菌γ-干扰素释放试验及临床应用专家意见(2021年版). 中华结核和呼吸杂志, 2022, 45(2):143-150. doi: 10.3760/cma.j.cn112147-20211110-00794. doi: 10.3760/cma.j.cn112147-20211110-00794
[14]	Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest, 2010, 137(4):952-968. doi: 10.1378/chest.09-2350. doi: 10.1378/chest.09-2350 URL
[15]	Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest, 2012, 142(1):63-75. doi: 10.1378/chest.11-3157. doi: 10.1378/chest.11-3157 URL
[16]	Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, et al. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J, 2011, 30(8):694-700. doi: 10.1097/INF.0b013e318214b915. doi: 10.1097/INF.0b013e318214b915 pmid: 21427627
[17]	Zhou XX, Liu YL, Zhai K, et al. Body Fluid Interferon-γ Release Assay for Diagnosis of Extrapulmonary Tuberculosis in Adults: A Systematic Review and Meta-Analysis. Sci Rep, 2015, 5:15284. doi: 10.1038/srep15284. doi: 10.1038/srep15284 URL
[18]	Luo Y, Tan Y, Yu J, et al. The Performance of Pleural Fluid T-SPOT.TB Assay for Diagnosing Tuberculous Pleurisy in China: A Two-Center Prospective Cohort Study. Front Cell Infect Microbiol, 2019, 9:10. doi: 10.3389/fcimb.2019.00010. doi: 10.3389/fcimb.2019.00010 URL
[19]	Wang F, Yu J, Zhou Y, et al. The Use of TB-Specific Antigen/Phytohemagglutinin Ratio for Diagnosis and Treatment Monitoring of Extrapulmonary Tuberculosis. Front Immunol, 2018, 9:1047. doi: 10.3389/fimmu.2018.01047. doi: 10.3389/fimmu.2018.01047 URL
[20]	Pan L, Jia H, Liu F, et al. Risk factors for false-negative T-SPOT.TB assay results in patients with pulmonary and extra-pulmonary TB. J Infect, 2015, 70(4):367-380. doi: 10.1016/j.jinf.2014.12.018. doi: 10.1016/j.jinf.2014.12.018 URL
[21]	Meier NR, Jacobsen M, Ottenhoff THM, et al. A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis. Front Immunol, 2018, 9:2476. doi: 10.3389/fimmu.2018.02476. doi: 10.3389/fimmu.2018.02476 URL
[22]	Whitworth HS, Badhan A, Boakye AA, et al. Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study. Lancet Infect Dis, 2019, 19(2):193-202. doi: 10.1016/S1473-3099(18)30613-3. doi: S1473-3099(18)30613-3 pmid: 30655049
[23]	Pourakbari B, Mamishi S, Benvari S, et al. Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube interferon-γ release assays: A systematic review and meta-analysis. Adv Med Sci, 2019, 64(2):437-443. doi: 10.1016/j.advms.2019.09.001. doi: 10.1016/j.advms.2019.09.001 URL
[24]	Sotgiu G, Saderi L, Petruccioli E, et al. QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. J Infect, 2019, 79(5):444-453. doi: 10.1016/j.jinf.2019.08.018. doi: 10.1016/j.jinf.2019.08.018 URL
[25]	潘丽萍, 高孟秋, 贾红彦, 等. 新型结核分枝杆菌特异性细胞免疫反应检测技术对结核病辅助诊断的价值评估. 中华结核和呼吸杂志, 2021, 44(5):443-449. doi: 10.3760/cma.j.cn112147-20200821-00916. doi: 10.3760/cma.j.cn112147-20200821-00916
[26]	Petrone L, Vanini V, Chiacchio T, et al. Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection. Tuberculosis (Edinb), 2018, 111:147-153. doi: 10.1016/j.tube.2018.06.005. doi: 10.1016/j.tube.2018.06.005 URL
[27]	Qiu X, Xiong T, Su X, et al. Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis. BMC Infect Dis, 2019, 19(1):924. doi: 10.1186/s12879-019-4466-5. doi: 10.1186/s12879-019-4466-5 URL
[28]	Syed Ahamed Kabeer B, Raman B, Thomas A, et al. Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One, 2010, 5(2):e9051. doi: 10.1371/journal.pone.0009051. doi: 10.1371/journal.pone.0009051 URL
[29]	Blauenfeldt T, Heyckendorf J, Graff Jensen S, et al. Development of a one-step probe based molecular assay for rapid immunodiagnosis of infection with M.tuberculosis using dried blood spots. PLoS One, 2014, 9(9):e105628. doi: 10.1371/journal.pone.0105628. doi: 10.1371/journal.pone.0105628 URL
[30]	Blauenfeldt T, Villar-Hernández R, García-García E, et al. Diagnostic Accuracy of Interferon Gamma-Induced Protein 10 mRNA Release Assay for Tuberculosis. J Clin Microbiol, 2020, 58(10):e00848-20. doi: 10.1128/JCM.00848-20. doi: 10.1128/JCM.00848-20
[31]	Pan L, Huang M, Jia H, et al. Diagnostic Performance of a Novel CXCL10 mRNA Release Assay for Mycobacterium tuberculosis Infection. Front Microbiol, 2022, 13:825413. doi: 10.3389/fmicb.2022.825413. doi: 10.3389/fmicb.2022.825413 URL
[32]	Mamishi S, Pourakbari B, Teymuri M, et al. Diagnostic accuracy of IL-2 for the diagnosis of latent tuberculosis: a systema-tic review and meta-analysis. Eur J Clin Microbiol Infect Dis, 2014, 33(12):2111-2119. doi: 10.1007/s10096-014-2190-z. doi: 10.1007/s10096-014-2190-z URL
[33]	Suzukawa M, Akashi S, Nagai H, et al. Combined Analysis of IFN-γ, IL-2, IL-5, IL-10, IL-1RA and MCP-1 in QFT Supernatant Is Useful for Distinguishing Active Tuberculosis from Latent Infection. PLoS One, 2016, 11(4):e0152483. doi: 10.1371/journal.pone.0152483. doi: 10.1371/journal.pone.0152483 URL
[34]	Suter-Riniker F, Berger A, Mayor D, et al. Clinical significance of interleukin-2/gamma interferon ratios in Mycobacterium tuberculosis-specific T-cell signatures. Clin Vaccine Immunol, 2011, 18(8):1395-1396. doi: 10.1128/CVI.05013-11. doi: 10.1128/CVI.05013-11 pmid: 21632888
[35]	Biselli R, Mariotti S, Sargentini V, et al. Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. Clin Microbiol Infect, 2010, 16(8):1282-1284. doi: 10.1111/j.1469-0691.2009.03104.x. doi: 10.1111/j.1469-0691.2009.03104.x URL
[36]	Santin M, Morandeira-Rego F, Alcaide F, et al. Detection of interleukin-2 is not useful for distinguishing between latent and active tuberculosis in clinical practice: a prospective cohort study. Clin Microbiol Infect, 2016, 22(12): 1007.e1-1007.e5. doi: 10.1016/j.cmi.2016.09.004. doi: 10.1016/j.cmi.2016.09.004
[37]	Chiappini E, Della Bella C, Bonsignori F, et al. Potential role of M.tuberculosis specific IFN-γ and IL-2 ELISPOT assays in discriminating children with active or latent tuberculosis. PLoS One, 2012, 7(9):e46041. doi: 10.1371/journal.pone.0046041. doi: 10.1371/journal.pone.0046041 URL
[38]	Della Bella C, Spinicci M, Grassi A, et al. Novel M.tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis. PLoS One, 2018, 13(6):e0197825. doi: 10.1371/journal.pone.0197825. doi: 10.1371/journal.pone.0197825 URL
[39]	Hwai H, Chen YY, Tzeng SJ. B-Cell ELISpot Assay to Quantify Antigen-Specific Antibody-Secreting Cells in Human Peripheral Blood Mononuclear Cells. Methods Mol Biol, 2018, 1808:133-141. doi: 10.1007/978-1-4939-8567-8_11. doi: 10.1007/978-1-4939-8567-8_11 pmid: 29956179
[40]	Sebina I, Cliff JM, Smith SG, et al. Long-lived memory B-cell responses following BCG vaccination. PLoS One, 2012, 7(12):e51381. doi: 10.1371/journal.pone.0051381. doi: 10.1371/journal.pone.0051381 URL
[41]	Joosten SA, van Meijgaarden KE, Del Nonno F, et al. Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment. PLoS Pathog, 2016, 12(6):e1005687. doi: 10.1371/journal.ppat.1005687. doi: 10.1371/journal.ppat.1005687 URL
[42]	Gindeh A, Owolabi O, Donkor S, et al. Mycobacterium tuberculosis-specific plasmablast levels are differentially modulated in tuberculosis infection and disease. Tuberculosis (Edinb), 2020, 124:101978. doi: 10.1016/j.tube.2020.101978. doi: 10.1016/j.tube.2020.101978 URL
[43]	Ashenafi S, Aderaye G, Zewdie M, et al. BCG-specific IgG-secreting peripheral plasmablasts as a potential biomarker of active tuberculosis in HIV negative and HIV positive patients. Thorax, 2013, 68(3):269-276. doi: 10.1136/thoraxjnl-2012-201817. doi: 10.1136/thoraxjnl-2012-201817 pmid: 22923457
[44]	Sudbury EL, Clifford V, Messina NL, et al. Mycobacterium tuberculosis-specific cytokine biomarkers to differentiate active TB and LTBI: A systematic review. J Infect, 2020, 81(6):873-881. doi: 10.1016/j.jinf.2020.09.032. doi: 10.1016/j.jinf.2020.09.032 pmid: 33007340
[45]	Day CL, Abrahams DA, Lerumo L, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol, 2011, 187(5):2222-2232. doi: 10.4049/jimmunol.1101122. doi: 10.4049/jimmunol.1101122 URL
[46]	Harari A, Rozot V, Bellutti Enders F, et al. Dominant TNF-α + Mycobacterium tuberculosis-specific CD4 + T cell responses discriminate between latent infection and active disease. Nat Med, 2011, 17(3):372-376. doi: 10.1038/nm.2299. doi: 10.1038/nm.2299 URL
[47]	Rozot V, Patrizia A, Vigano S, et al. Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin Infect Dis, 2015, 60(3):432-437. doi: 10.1093/cid/ciu795. doi: 10.1093/cid/ciu795 URL
[48]	Kim JY, Kang YA, Park JH, et al. An IFN-γ and TNF-α dual release fluorospot assay for diagnosing active tuberculosis. Clin Microbiol Infect, 2020, 26(7):928-934. doi: 10.1016/j.cmi.2019.11.003. doi: 10.1016/j.cmi.2019.11.003 URL
[49]	Kim JY, Park JH, Kim MC, et al. Combined IFN-γ and TNF-α release assay for differentiating active tuberculosis from latent tuberculosis infection. J Infect, 2018, 77(4):314-320. doi: 10.1016/j.jinf.2018.04.011. doi: 10.1016/j.jinf.2018.04.011 URL
[50]	Adekambi T, Ibegbu CC, Cagle S, et al. Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J Clin Invest, 2015, 125(5):1827-1838. doi: 10.1172/JCI77990. doi: 10.1172/JCI77990 pmid: 25822019
[51]	《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础专业和临床专业学术部. 结核病患者外周血淋巴细胞亚群检测及临床应用专家共识. 中国防痨杂志, 2020, 42(10):1009-1016. doi: 10.3969/j.issn.1000-6621.2020.10.001. doi: 10.3969/j.issn.1000-6621.2020.10.001
[52]	Agranoff D, Fernandez-Reyes D, Papadopoulos MC, et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet, 2006, 368(9540):1012-1021. doi: 10.1016/S0140-6736(06)69342-2. doi: 10.1016/S0140-6736(06)69342-2 pmid: 16980117
[53]	De Groote MA, Sterling DG, Hraha T, et al. Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis. J Clin Microbiol, 2017, 55(10):3057-3071. doi: 10.1128/JCM.00467-17. doi: 10.1128/JCM.00467-17 pmid: 28794177
[54]	Yang Q, Chen Q, Zhang M, et al. Identification of eight-protein biosignature for diagnosis of tuberculosis. Thorax, 2020, 75(7):576-583. doi: 10.1136/thoraxjnl-2018-213021. doi: 10.1136/thoraxjnl-2018-213021 URL
[55]	Sun H, Pan L, Jia H, et al. Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection. Front Microbiol, 2018, 9:1267. doi: 10.3389/fmicb.2018.01267. doi: 10.3389/fmicb.2018.01267 URL
[56]	Singer SN, Ndumnego OC, Kim RS, et al. Plasma host protein biomarkers correlating with increasing Mycobacterium tuberculosis infection activity prior to tuberculosis diagnosis in people living with HIV. EBioMedicine, 2022, 75:103787. doi: 10.1016/j.ebiom.2021.103787. doi: 10.1016/j.ebiom.2021.103787 URL
[57]	Mutavhatsindi H, Calder B, McAnda S, et al. Identification of novel salivary candidate protein biomarkers for tuberculosis diagnosis: A preliminary biomarker discovery study. Tuberculosis (Edinb), 2021, 130:102118. doi: 10.1016/j.tube.2021.102118. doi: 10.1016/j.tube.2021.102118 URL
[58]	Arya R, Dabral D, Faruquee HM, et al. Serum Small Extracellular Vesicles Proteome of Tuberculosis Patients Demonstrated Deregulated Immune Response. Proteomics Clin Appl, 2020, 14(1):e1900062. doi: 10.1002/prca.201900062. doi: 10.1002/prca.201900062
[59]	Chen J, Han YS, Yi WJ, et al. Serum sCD14, PGLYRP2 and FGA as potential biomarkers for multidrug-resistant tuberculosis based on data-independent acquisition and targeted proteomics. J Cell Mol Med, 2020, 24(21):12537-12549. doi: 10.1111/jcmm.15796. doi: 10.1111/jcmm.15796 URL
[60]	Kaewseekhao B, Roytrakul S, Yingchutrakul Y, et al. Proteomic analysis of infected primary human leucocytes revealed PSTK as potential treatment-monitoring marker for active and latent tuberculosis. PLoS One, 2020, 15(4):e0231834. doi: 10.1371/journal.pone.0231834. doi: 10.1371/journal.pone.0231834 URL
[61]	Pan L, Zhang X, Jia H, et al. Label-Free Quantitative Proteomics Identifies Novel Biomarkers for Distinguishing Tuberculosis Pleural Effusion from Malignant Pleural Effusion. Proteomics Clin Appl, 2020, 14(1):e1900001. doi: 10.1002/prca.201900001. doi: 10.1002/prca.201900001
[62]	Shen Y, Xun J, Song W, et al. Discovery of Potential Plasma Biomarkers for Tuberculosis in HIV-Infected Patients by Data-Independent Acquisition-Based Quantitative Proteomics. Infect Drug Resist, 2020, 13:1185-1196. doi: 10.2147/IDR.S245460. doi: 10.2147/IDR.S245460 URL
[63]	Garay-Baquero DJ, White CH, Walker NF, et al. Comprehensive plasma proteomic profiling reveals biomarkers for active tuberculosis. JCI Insight, 2020, 5(18):e137427. doi: 10.1172/jci.insight.137427. doi: 10.1172/jci.insight.137427 URL
[64]	Penn-Nicholson A, Hraha T, Thompson EG, et al. Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. PLoS Med, 2019, 16(4):e1002781. doi: 10.1371/journal.pmed.1002781. doi: 10.1371/journal.pmed.1002781 URL
[65]	Shi J, Li P, Zhou L, et al. Potential biomarkers for antidiastole of tuberculous and malignant pleural effusion by proteome analysis. Biomark Med, 2019, 13(2):123-133. doi: 10.2217/bmm-2018-0200. doi: 10.2217/bmm-2018-0200 URL

时间/文献编号	标本类型	研究技术	分子标识	期刊名称
2022^[56]	血浆	MRM-MS	CD14/A2GL/NID1/SCTM1/A1AG1	EBioMedicine
2021^[57]	唾液	LC-MS/MS	NAXE/SERPINA3/PSMB6/IGKV1D-33/ SERPINI1	Tuberculosis
2020^[58]	血清	iTRAQ	KYAT3/SERPINA1/HP/APOC3	Proteomics Clin Appl
2020^[59]	血清	DIA-MS	sCD14/PGLYRP2/FGA	J Cell Mol Med
2020^[60]	淋巴细胞	GeLC-MS/MS	PSTK	PLoS One
2020^[61]	血浆	非标记定量蛋白质组学	AGP1/ORM2/C9	Proteomics Clin Appl
2020^[54]	血浆	蛋白芯片	I-TAC/I-309/MIG/Granulysin/FAP/ MEP1B/Furin/LYVE-1	Thorax
2020^[62]	血浆	DIA-MS	AMACR/LDHB/RAP1B	Infect Drug Resist
2020^[63]	血浆	q3D LC-MS	CFHR5/LRG1/CRP/LBP/SAA1	JCI Insight
2019^[64]	血清	蛋白芯片	C9/IGFBP-2/CD79A/MXRA-7/NrCAM	PLoS Med
2019^[65]	胸腔积液	iTRAQ	FN/CTSG/LTA4H	Biomark Med
2018^[55]	血浆	非标记定量蛋白质组学	AGP1/ACT/CDH1	Front Microbiol
2017^[53]	血清	蛋白芯片	SYWC/Kallistatin/C9/Gelsolin/Testican-2/ Aldolase C	J Clin Microbiol